Investing
Walgreen must face US lawsuit alleging false claims over hepatitis C drugs
© Reuters. FILE PHOTO: Pigeons are seen resting on signage for Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo
(Reuters) – A federal appeals court on Tuesday revived a lawsuit by the United States and Virginia that accused Walgreens Boots Alliance (NASDAQ:) of misrepresenting that some patients met Virginia’s Medicaid-eligibility requirements for expensive hepatitis C drugs.
The 4th U.S. Circuit Court of Appeals said the governments plausibly alleged that Walgreen’s misrepresentations were material, and vacated a lower court ruling to the contrary.
Walgreen’s had been accused of violating the federal False Claims Act and Virginia state law.
Read the full article here
-
Investing5 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Passive Income5 days ago
How to Create a Routine That Balances Rest and Business Success
-
Side Hustles6 days ago
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles3 days ago
A Macy’s Employee Made Accounting Errors Worth $132 Million
-
Investing2 days ago
Factbox-How Trump can overhaul US financial regulators when he takes office By Reuters
-
Passive Income6 days ago
Customers Want More Than Just a Product — Here’s How to Keep Up
-
Side Hustles5 days ago
Gift the Power of Language Learning with This Limited-Time Price on Babbel
-
Investing3 days ago
Palantir assigned Street-high targets by Wedbush and BofA By Investing.com